Short Interest in Inhibrx, Inc. (NASDAQ:INBX) Expands By 5.8%

Inhibrx, Inc. (NASDAQ:INBX) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,090,000 shares, a growth of 5.8% from the November 15th total of 1,030,000 shares. Approximately 11.0% of the company’s shares are short sold. Based on an average daily trading volume, of 84,700 shares, the short-interest ratio is presently 12.9 days.

Insider Buying and Selling at Inhibrx

In related news, Director Jon Faiz Kayyem purchased 69,686 shares of Inhibrx stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now directly owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.20% of the company’s stock.

Inhibrx Price Performance

Shares of NASDAQ:INBX opened at $14.55 on Wednesday. The business’s 50 day moving average is $15.33 and its 200 day moving average is $14.78. Inhibrx has a 52-week low of $10.80 and a 52-week high of $18.95.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.